Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies

Expert Review of Hematology
Maria Chiara FinazziAlessandro Rambaldi

Abstract

Myelofibrosis (MF) is the most aggressive form among Philadelphia negative (Ph-) myeloproliferative neoplasms (MPNs). In the last years, the mutational landscape of MF has expanded remarkably by the identification of additional recurrent mutations, called subclonal mutations. Areas covered: Here we describe the available data about the currently identified subclonal mutations and their prognostic value in MF patients. We also review the practical value of including such molecular information in available prognostic models for both outcome prediction and possibly treatment decision with regards to transplant indication. Lastly, we covered the available data on the application of molecular markers for minimal residual disease (MRD) monitoring after transplantation. Expert commentary: The demonstration of the prognostic value of additional mutations suggests to define this molecular profile at diagnosis and when an allogeneic transplant can be advised, particularly in younger patients. The presence of molecular markers might offer the possibility to evaluate the depth of remission and to monitor MRD after transplantation. Prospective clinical studies are needed to validate the use of this molecular data in the routine clinical pra...Continue Reading

References

Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Feb 3, 2007·The New England Journal of Medicine·Linda M ScottAnthony R Green
Aug 23, 2007·Blood·Giovanni BarosiUNKNOWN Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Jul 18, 2009·Leukemia·N CarbucciaM J Mozziconacci
Jul 31, 2009·Cancer·Alois GratwohlUNKNOWN European Group for Blood and Marrow Transplantation and the European Leukemia Net
Jan 28, 2010·Nature Genetics·Eva Martinez-Garcia, Jonathan D Licht
May 4, 2010·Nature·Johanna C ScheuermannJürg Müller
Jul 6, 2010·Nature Genetics·Thomas ErnstNicholas C P Cross
Aug 21, 2010·Leukemia·H MakishimaJ P Maciejewski
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Sep 10, 2011·Annals of Hematology·Luz Martínez-AvilésBeatriz Bellosillo
Sep 17, 2011·Blood·Paola GuglielmelliAlessandro M Vannucchi
Jan 28, 2012·British Journal of Haematology·Haefaa AlchalbyNicolaus Kröger
Sep 11, 2012·Trends in Immunology·Malini RaghavanNatasha Del Cid
Apr 5, 2013·American Journal of Hematology·Emna AbdelhamidClaude Preudhomme
Apr 27, 2013·Leukemia·A M VannucchiA Tefferi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.